COVID-19 in patients with myasthenia gravis.
Muscle Nerve
; 62(2): 254-258, 2020 08.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2209145
ABSTRACT
INTRODUCTION:
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about its potential impact on patients with myasthenia gravis (MG).METHODS:
We studied the clinical course of COVID-19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies) between April 1, 2020-April 30-2020.RESULTS:
Two patients required intubation for hypoxemic respiratory failure, whereas one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications.DISCUSSION:
Our findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population.Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Pneumopathie virale
/
Insuffisance respiratoire
/
Immunoglobulines par voie veineuse
/
Infections à coronavirus
/
Anticorps monoclonaux humanisés
/
Facteurs immunologiques
/
Hypoxie
/
Myasthénie
Type d'étude:
Étude pronostique
Les sujets:
Covid long
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
/
Adulte d'âge moyen
langue:
Anglais
Revue:
Muscle Nerve
Année:
2020
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS